Want to see CNTB full AI Analyst Report?
CNTB Stock Chart & Stats
$2.14
-$0.06(-2.73%)
At close: 4:00 PM EDT
$2.14
-$0.06(-2.73%)
Day’s Range― - ―
52-Week Range$1.23 - $3.82
Previous CloseN/A
Volume327.99K
Average Volume (3M)97.97K
Market Cap
$154.92M
Enterprise Value$118.77
Total Cash (Recent Filing)$31.49M
Total Debt (Recent Filing)$596.00K
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
Nov 18, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding62,974,308
10 Day Avg. Volume111,495
30 Day Avg. Volume97,966
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.74
Price to Sales (P/S)2452.52
P/FCF Ratio-3.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.83Price Target Upside266.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-7.45
Revenue Forecast (FY)$34.24M
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressCompleting enrollment in two Phase 2 studies advances rademikibart toward a meaningful clinical readout. Positive controlled data could support discussions with the FDA and establish a path toward Phase 3 development.
Development Pipeline PotentialRademikibart is being tested in clinically important asthma and COPD settings where treatment failure and impaired lung function represent substantial unmet needs. Demonstrated benefit could expand the program’s strategic and commercial relevance.
Low Financial LeverageVery low debt limits interest obligations and reduces balance-sheet pressure while the company funds clinical development. This provides greater financial flexibility than a similarly loss-making biotech carrying substantial borrowing.
Bears Say
Lack Of Durable Product RevenueThe absence of approved products leaves Connect Biopharma without a dependable operating revenue base. Until a candidate reaches commercialization or a partnership generates recurring economics, financial performance will remain highly dependent on external funding.
Persistent Cash BurnHeavy operating and free-cash-flow deficits indicate that clinical development currently consumes substantial capital without internally generated funding. Continued investment will likely require spending controls, partnerships, or additional financing.
Shrinking Capital BaseThe sharp reduction in equity and assets reflects cumulative losses and a weaker financial cushion. A smaller capital base can limit development flexibility and increase reliance on potentially dilutive financing before clinical programs mature.
Connect Biopharma Holdings News
CNTB FAQ
What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $1.23 and its highest was $3.82 in the past 12 months.
What is Connect Biopharma Holdings’s market cap?
Connect Biopharma Holdings’s market cap is $154.92M.
When is Connect Biopharma Holdings’s upcoming earnings report date?
Connect Biopharma Holdings’s upcoming earnings report date is Nov 18, 2026 which is in 88 days.
How were Connect Biopharma Holdings’s earnings last quarter?
Connect Biopharma Holdings released its earnings results on Aug 12, 2026. The company reported -$0.271 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.047.
Is Connect Biopharma Holdings overvalued?
According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
Does Connect Biopharma Holdings pay dividends?
Connect Biopharma Holdings does not currently pay dividends.
What is Connect Biopharma Holdings’s EPS estimate?
Connect Biopharma Holdings’s EPS estimate is -0.27.
How many shares outstanding does Connect Biopharma Holdings have?
Connect Biopharma Holdings has 62,974,308 shares outstanding.
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Connect Biopharma Holdings reported an EPS of -$0.271 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went up 9.013%.
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
Currently, no hedge funds are holding shares in CNTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Connect Biopharma Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.83 (266.04% Upside)
$7.83 (266.04% Upside)
Insider Transactions
Bought Shares
Worth $370.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-47.45%
Trailing 12-Months
Company Description
Connect Biopharma Holdings
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
CNTB Stock 12 Month Forecast
Average Price Target
$7.83
▲(266.04% Upside)
Technical Analysis
Scinai Immunotherapeutics
―
GT Biopharma
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Ownership Overview
21.29% Insiders
0.04% Mutual Funds
16.28% Other Institutional Investors
60.93% Public Companies and
Individual Investors